Page 3 - Cipla

Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma

Promoters Shirin Hamied, Rumana Hamied, Samina Hamied and Okasa Pharma Private Limited have sold 2.53 per cent shares of Cipla for an undisclosed amount

Bharti Airtel, Cipla, Paytm, Colgate among seven stocks to track on May 15

At 6:55 AM, GIFT Nifty futures was trading 73 points higher at 22,382.50 levels compared to Nifty50 futures, indicating a positive start for the bourses

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said

Cipla: Timely new launches, India outperformance key for margin gains

Brokerages maintain add/buy rating on the stock

Cipla surges 6% in weak market on upbeat management commentary

The management has guided 24.5 per cent-25.5 per cent Ebitda margin for FY25

Cipla Q4 results: Profit rises 78.5% to Rs 939 crore, revenue up 7%

Cipla Q4FY24 results: The company board has recommended a final dividend of Rs 13 per equity share, to be paid within 30 days from the date of the annual general meeting (AGM)

Cipla Q4 Results Preview: Profits may jump up to 75% on higher volumes

Cipla may show a 3-10 per cent jump in its topline year-on-year (Y-o-Y), registering revenues in the range of Rs 5,939 crore and Rs 6,292 crore

USFDA issues Form 483 with 1 inspectional observation to Cipla's Maha unit

Pharma major Cipla Ltd on Wednesday said it has received one inspectional observation in Form 483 from the US health regulator for its manufacturing facility at Kurkumbh in Maharashtra. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. A routine current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the company's manufacturing facility at Kurkumbh, Maharashtra from April 29, 2024, to May 8, 2024, Cipla said in a regulatory filing. "On conclusion of the inspection, the company has received one inspectional observation in Form 483," it added. The company will work closely with the USFDA and is committed to addressing this observation comprehensively within the stipulated time, Cipla said.

Anand Rathi recommends buy on Dr.Reddys, Cipla and Piramal Enterprises

Stock picks by Anand Rathi: DR Reddy shows a strong uptrend with higher highs and higher lows on a weekly scale

Cipla, Glenmark recall drugs from US over manufacturing issues: USFDA

Drug makers Cipla and Glenmark are recalling products from the American market due to manufacturing issues, according to the US health regulator. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), a New Jersey-based subsidiary of Cipla is recalling 59,244 packs of Ipratropium Bromide and Albuterol Sulfate Inhalation Solution. The medication, produced at the company's Indore SEZ plant, is used to help control the symptoms of lung diseases, such as asthma, chronic bronchitis and emphysema. Cipla USA is recalling the affected lot due to "short fill". There were complaints of less fill volume in respule and few drops of liquid observed in the intact pouch, USFDA said. Cipla initiated the Class II recall in the US market on March 26 this year. USFDA also said that Glenmark Pharma is recalling 3,264 bottles of Diltiazem Hydrochloride extended-release capsules indicated for high blood pressure. The US-based arm of the company -- Glenmark ...

Stock to Watch, April 29: ICICI Bk, HCL Tech, YES Bk, Ircon, Maruti, Cipla

Stocks to Watch on Monday, April 29,2024: The net profit of private lender ICICI Bank rose by 17.4 per cent to Rs 10,708 crore in the fourth quarter of financial year 2023-24 (Q4FY24)

Cipla gets Rs 1.83 cr penalty for claiming inadmissible transitional credit

Pharma major Cipla Ltd on Friday said it has been imposed a penalty of Rs 1.83 crore by the GST authority for claiming inadmissible transitional credit on education cess. The company has received an order from the Principal Commissioner of CGST & Central Excise, Mumbai, Maharashtra imposing a penalty of Rs 1,83,17,388 under applicable provisions of the Central Goods and Services Tax Act, 2017 and Maharashtra Goods and Services Tax Act, 2017, Cipla said in a regulatory filing. "The order has been passed by the GST Authority on the contention that the company has claimed inadmissible transitional credit on education cess during the transition from excise regime to GST regime in FY 2017-18 and has ordered recovery of the same with penalty," it added. Cipla further said that based on an assessment of facts and prevailing law, it will file necessary appeals with the appellate authority in this regard. There is no material impact on the company's financials or operations due to the said

Cipla Health signs agreement, strengthens beauty play with Ivia's brands

Cipla Health strengthens beauty play in Tier II-VI towns with Ivia Beaute's cosmetics, personal care distribution and marketing biz

Cipla to acquire Ivia Beaute's cosmetics, personal care biz for Rs 130 cr

Pharma major Cipla Ltd will acquire the cosmetics and personal care distribution and marketing business of Ivia Beaute Pvt Ltd, including the latter's brands Astaberry, Ikin and Bhimsaini, on a worldwide basis for Rs 130 crore, according to a regulatory filing by the company. Cipla Health Ltd (CHL), a wholly owned subsidiary and consumer healthcare arm, has signed a Business Transfer Agreement (BTA) for purchase of the distribution and marketing business undertaking of the cosmetics and personal care business of Ivia Beaute Pvt Ltd, Cipla said. This strategic move is aligned with Cipla's focus on enhancing its consumer healthcare and wellness portfolio, it added. The acquisition will include Ivia Beaute's brands namely Astaberry, Ikin and Bhimsaini on a worldwide basis, the company said. On the cost of acquisition, Cipla said it will be "Rs 130 crore on the closing date and Rs 110 crore contingent upon achievement of certain financial parameters (milestones) for next 3 years as ...

Stocks to Watch today: Jio Financial, Cipla, Vi, Brigade, Vedanta, Aster DM

Stocks to watch on Tuesday, April 16, 2024: Balrampur Chini, Bandhan Bank, Exide, GNFC, Hind Copper, India Cement, Metropolis, National Aluminium, PEL, SAIL and Zee are the 11 stocks in F&O ban today.

MNCs partner Indian firms to boost market reach in pharmaceutical sector

MNC's like AstraZeneca's have also collaborated with Mankind Pharma to distribute asthma medication in India further highlights this trend's reach across therapeutic areas

Big plans ahead: Cipla looks for shot in the arm in niche areas

Open to licensing, collaboration in anti-diabetes space

Cipla receives approval from drug regulator CDSCO for UTI drug

Plazomicin is a new intravenous (IV) aminoglycoside that has demonstrated efficacy and safety in clinical trials compared to meropenem (antibacterial agent)

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Cipla eyes acquisitions, inorganic partnerships in US, European markets

Drug major Cipla is eyeing acquisitions and inorganic partnerships in the US market while consolidating its presence across segments in the domestic market. The Mumbai-based company is also looking to improve the top line in Europe and margin expansion in South Africa. "Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call. The drug maker would also focus on commercial execution of existing portfolios and resolution of USFDA observations, he added. In the South African market, Cipla would build on its performance aided by growth in private and select tender business with greater emphasis on margin expansion, Adukia stated. "In emerging markets and Europe, top priority is to improve top line while margins are maintained at sustainable levels," he said. As per the yearly trend, the fourth quarter will have